Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients

Clinical Infectious Diseases

Volumn 29, Issue 2, 1999, Pages 441-443

  Roberts, Afsoon D ^a   Muesing, Richard A ^a   Parenti, David M ^a   Hsia, Judy ^a   Wasserman, Alan G ^a   Simon, Gary L ^a,b  

^a Division of Infectious Diseases   (United States)

^b GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; DIDANOSINE; HIGH DENSITY LIPOPROTEIN; INDINAVIR; LAMIVUDINE; LIPID; LIPOPROTEIN; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE;

ARTICLE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; METABOLIC DISORDER; PRIORITY JOURNAL;

EID: 0032776658     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/520231     Document Type: Article

References (12)

1. 1. Mann M, Piazza-Hepp T, Koller E, Gilbert C. Abnormal fat distribution in AIDS patients following protease inhibitor therapy: FOA summary [abstract no 412]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, Virginia: Foundation for Retrovirology and Human Health, 1998.
2. 2. Hengel RL, Geary JAM, Vuchetich MA, et al. Multiple symmetrical lipomatosis associated with protease inhibitor therapy [abstract no 407]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, Virginia: Foundation for Retrovirology and Human Health, 1998.
3. 3. Rosenberg HE, Mulder S, Sepkowitz KA, Giordano MF. "Protease-paunch" in HIV positive persons receiving protease inhibitor therapy, incidence, risk and endocrinologic evaluation [abstract no 408]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, Virginia: Foundation for Retrovirology and Human Health, 1998.
4. 4. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. Buffalo hump in HIV-infected patients on antiretroviral therapy [abstract no 409]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, Virginia: Foundation for Retrovirology and Human Health, 1998.
5. 5. Roth VR, Angel JB, Kravcik S. Development of a cervical fat pad following treatment with HIV-1 protease inhibitors [abstract no 411]. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, Virginia: Foundation for Retrovirology and Human Health, 1998.
6. 6. Carr A, Samaras K, Burton S, Freud J, Chrisholm DJ, Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12: F51-8.
7. 7. Carr A, Samaras K, Chisolm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet 1988;351:1881-3.
8. 8. Gidez LT, Miller GH, Burnstein M, Slagle S, Eder HA. Separation and quantitation of subclasses of human plasma high density lipoproteins by a simple precipitation procedure. J Lipid Res 1982;23:1206-23.
9. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-54.
10. 10. Sullivan AK, Nelson MR. Marked hyperlipidemia on ritonavir therapy. AIDS 1997;11:938-9.
11. 11. Weinroth SE, Parenti DM, Simon GL. Wasting syndrome in AIDS: pathophysiologic mechanisms and therapeutic approaches. Infect Agents Dis 1995;4:76-94.
12. 12. Boston AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein (a) and coronary heart disease in men aged 55 years and younger. JAMA 1996;276:544-8.